{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T18:11:29Z","timestamp":1791223889509,"version":"4.1.0"},"reference-count":18,"publisher":"Royal College of Psychiatrists","issue":"2","license":[{"start":{"date-parts":[[2018,1,2]],"date-time":"2018-01-02T00:00:00Z","timestamp":1514851200000},"content-version":"unspecified","delay-in-days":5449,"URL":"https:\/\/www.cambridge.org\/core\/terms"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Psychiatry"],"published-print":{"date-parts":[[2003,2]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Few double-blind trials have examined the efficacy of a combination of a mood stabiliser and an atypical antipsychotic in acute mania.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aims<\/jats:title><jats:p>To determine the efficacy of risperidone in combination with a mood stabiliser in acute mania.<\/jats:p><\/jats:sec><jats:sec><jats:title>Method<\/jats:title><jats:p>Patients taking a mood stabiliser were randomised to 3 weeks' treatment with risperidone (<jats:italic>n<\/jats:italic>=75) or placebo (<jats:italic>n<\/jats:italic>=76).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Young Mania Rating Scale (YMRS) scores improved rapidly with significantly greater reductions at week 1 in the risperidone group compared with the placebo group. At end-point YMRS scores decreased by 14.5 and 10.3 points in the risperidone and placebo groups, respectively. Significant improvements <jats:italic>v.<\/jats:italic> placebo (<jats:italic>P<\/jats:italic> &lt; 0.05) were noted in the risperidone group on several other clinically meaningful measures. Additionally, a post hoc analysis excluding carbamazepine-treated patients (plasma concentrations of risperidone active moiety were 40% lower in this group) revealed significantly greater reductions (<jats:italic>P<\/jats:italic>=0.047) in YMRS scores in the risperidone group than in the placebo group. Incidence of adverse events was similar in both groups.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Risperidone is superior to placebo when used in combination with lithium or divalproex in acute mania.<\/jats:p><\/jats:sec>","DOI":"10.1192\/bjp.182.2.141","type":"journal-article","created":{"date-parts":[[2003,2,3]],"date-time":"2003-02-03T20:46:47Z","timestamp":1044305207000},"page":"141-147","source":"Crossref","is-referenced-by-count":206,"title":["Mood stabilisers plus risperidone or placebo in the treatment of acute mania"],"prefix":"10.1192","volume":"182","author":[{"given":"Laksami N.","family":"Yatham","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fred","family":"Grossman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilse","family":"Augustyns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduard","family":"Vieta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arun","family":"Ravindran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"170","published-online":{"date-parts":[[2018,1,2]]},"reference":[{"key":"S000712500026978X_ref18","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.133.5.429"},{"key":"S000712500026978X_ref14","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.59.1.62"},{"key":"S000712500026978X_ref11","unstructured":"Sachs G. S. , Printz D. J. , Kahn D. A. , et al (2000) The Expert Consensus Guideline Series: Medication treatment of bipolar disorder. Postgraduate Medicine, April Special Report, 1\u2013104."},{"key":"S000712500026978X_ref8","volume-title":"ECDEU Assessment Manual for Psychopharmacology, Revised","author":"Guy","year":"1976"},{"key":"S000712500026978X_ref7","doi-asserted-by":"publisher","DOI":"10.1177\/070674379704200211"},{"key":"S000712500026978X_ref5","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.155.1.12"},{"key":"S000712500026978X_ref4","first-page":"233","article-title":"Extrapyramidal Symptom Rating Scale (abstract)","volume":"7","author":"Chouinard","year":"1980","journal-title":"Canadian Journal of Neurological Science"},{"key":"S000712500026978X_ref3","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v61n0910"},{"key":"S000712500026978X_ref2","first-page":"1","article-title":"Practice guideline for the treatment of patients with bipolar disorder (revision)","volume":"159","year":"2002","journal-title":"American Journal of Psychiatry"},{"key":"S000712500026978X_ref1","volume-title":"Diagnostic and Statistical Manual of Mental Disorders","year":"1994"},{"key":"S000712500026978X_ref16","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v62n1011"},{"key":"S000712500026978X_ref12","first-page":"176","article-title":"Risperidone compared with both lithium and haloperidol in mania: double-blind randomized controlled trial","volume":"21","author":"Segal","year":"1998","journal-title":"Clinical Neuropharmacology"},{"key":"S000712500026978X_ref6","doi-asserted-by":"publisher","DOI":"10.1097\/00004850-199711000-00006"},{"key":"S000712500026978X_ref17","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1978.124"},{"key":"S000712500026978X_ref15","first-page":"351","article-title":"On the combination of independent two-sample tests of Wilcoxon","volume":"37","author":"van Elteren","year":"1960","journal-title":"Bulletin of the International Statistical Institute"},{"key":"S000712500026978X_ref10","doi-asserted-by":"publisher","DOI":"10.2466\/pr0.1962.10.3.799"},{"key":"S000712500026978X_ref9","doi-asserted-by":"publisher","DOI":"10.1111\/j.2044-8260.1967.tb00530.x"},{"key":"S000712500026978X_ref13","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.57.9.841"}],"container-title":["British Journal of Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S000712500026978X","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,6]],"date-time":"2019-05-06T23:47:19Z","timestamp":1557186439000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S000712500026978X\/type\/journal_article"}},"subtitle":["International, double-blind, randomised controlled trial"],"short-title":[],"issued":{"date-parts":[[2003,2]]},"references-count":18,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2003,2]]}},"alternative-id":["S000712500026978X"],"URL":"https:\/\/doi.org\/10.1192\/bjp.182.2.141","relation":{},"ISSN":["0007-1250","1472-1465"],"issn-type":[{"value":"0007-1250","type":"print"},{"value":"1472-1465","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,2]]}}}